

# Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.6	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	10	2.5	399.2	(191.1-734.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	2.8	179.3	(57.8-418.5)
Female	18	18.9	95.2	(56.4-150.5)	Female	1	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	5	2.4	209.1	(67.4-487.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	7.1	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
Female	6	5.0	120.0	(43.8-261.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	1.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	27	21.6	125.1	(82.4-182.0)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male				
Male	2	2.7	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	3	1.6	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.4	nc	(nc-nc)	Female	3	4.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	4	9.2	nc	(nc-nc)	Male	65	70.4	92.3	(71.3-117.7)
Female	4	7.2	nc	(nc-nc)	Female	55	57.9	94.9	(71.5-123.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	14.2	112.3	(64.2-182.5)	Male	10	8.4	118.9	(56.9-218.6)
Female	3	4.8	nc	(nc-nc)	Female	9	6.4	140.3	(64.0-266.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.5	nc	(nc-nc)	Male	5	2.2	230.1	(74.1-536.9)
Female	1	2.0	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	6	7.3	82.3	(30.0-179.1)
Female	44	46.0	95.7	(69.5-128.4)	Female	1	6.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.9	nc	(nc-nc)	Male	5	5.0	99.2	(32.0-231.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	14	19.6	71.4	(39.0-119.9)	Female	7	4.8	145.9	(58.5-300.7)
Female	12	17.1	70.3	(36.3-122.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	4.2	141.8	(51.8-308.7)
Male	7	3.6	196.0	(78.5-403.9)	Female	6	4.1	146.4	(53.5-318.7)
Female	0	0.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	52	50.4	103.1	(77.0-135.2)
Male	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	1.8	nc	(nc-nc)
Male	9	6.4	141.0	(64.3-267.6)	<b><u>Testis</u></b>				
Female	8	3.8	209.3	(90.1-412.4)	Male	2	1.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	8	6.2	129.3	(55.7-254.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	4.6	nc	(nc-nc)	Female	8	10.2	78.6	(33.8-154.9)
Female	3	3.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	191	182.2	104.9	(90.5-120.8)
Male	4	3.1	nc	(nc-nc)	Female	159	161.9	98.2	(83.6-114.7)
Female	0	1.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	27	26.0	103.8	(68.4-151.0)					
Female	27	23.4	115.2	(75.9-167.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	10	5.4	186.3	(89.2-342.7)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	6.0	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male				
Male	0	0.7	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	1	2.7	nc	(nc-nc)	Male	13	20.1	64.8	(34.5-110.8)
Female	2	2.4	nc	(nc-nc)	Female	19	18.1	105.2	(63.3-164.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	9.1	54.9	(17.7-128.1)	Male	3	6.7	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	4	5.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	4	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.6	88.5	(28.5-206.5)
Female	43	37.9	113.5	(82.1-152.9)	Female	8	4.5	177.8	(76.6-350.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.0	nc	(nc-nc)	Male	7	4.3	163.1	(65.3-336.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	10	13.7	72.9	(34.9-134.1)	Female	3	3.8	nc	(nc-nc)
Female	12	12.1	98.9	(51.0-172.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	2.6	nc	(nc-nc)	Male	30	36.7	81.7	(55.1-116.6)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	5.0	nc	(nc-nc)	Female	10	8.0	124.7	(59.7-229.4)
Female	6	2.7	218.2	(79.7-475.0)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	111	132.4	83.9	(69.0-101.0)
Female	0	0.4	nc	(nc-nc)	Female	150	125.1	119.9	(101.5-140.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	3.4	174.6	(63.8-380.1)	<b><u>All Sites / Types</u></b>				
Female	3	2.6	nc	(nc-nc)	Male	111	132.4	83.9	(69.0-101.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	2.5	nc	(nc-nc)	Female	150	125.1	119.9	(101.5-140.7)
Female	0	0.7	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	20	17.1	116.9	(71.4-180.5)	Male	111	132.4	83.9	(69.0-101.0)
Female	28	15.1	185.6	(123.3-268.3)	Female	150	125.1	119.9	(101.5-140.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chatham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	17.3	121.7	(75.3-186.0)	Male	11	8.5	128.8	(64.2-230.5)
Female	8	6.1	131.9	(56.8-259.8)	Female	7	5.9	118.0	(47.3-243.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	10	7.6	131.8	(63.1-242.4)
Female	63	45.8	137.6	(105.8-176.1)	Female	3	7.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	25	22.4	111.8	(72.3-165.0)	Female	11	5.0	218.6	(109.0-391.1)
Female	14	22.2	63.0	(34.4-105.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	4.9	nc	(nc-nc)
Male	7	3.9	178.6	(71.6-368.0)	Female	6	5.3	113.0	(41.2-245.9)
Female	0	1.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	74	55.5	133.4	(104.8-167.5)
Male	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	0.5	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	2.5	nc	(nc-nc)
Male	12	6.5	183.9	(94.9-321.3)	<b><u>Testis</u></b>				
Female	2	4.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	2.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	4.8	nc	(nc-nc)	Female	11	10.4	105.9	(52.8-189.6)
Female	7	3.8	186.4	(74.7-384.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	213	200.0	106.5	(92.7-121.8)
Male	2	3.1	nc	(nc-nc)	Female	183	177.4	103.1	(88.7-119.2)
Female	0	1.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	17	30.3	56.0	(32.6-89.7)					
Female	21	27.8	75.4	(46.7-115.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	32	35.5	90.1	(61.6-127.2)	Male	29	23.2	125.2	(83.9-179.9)
Female	16	14.1	113.4	(64.8-184.2)	Female	19	19.8	96.2	(57.9-150.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	7.1	nc	(nc-nc)	Male	6	5.7	104.8	(38.3-228.2)
Female	2	6.1	nc	(nc-nc)	Female	6	4.5	133.0	(48.6-289.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	1.2	nc	(nc-nc)	Male	25	19.6	127.6	(82.5-188.3)
Female	180	143.5	125.5	(107.8-145.2)	Female	16	18.5	86.6	(49.5-140.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	6.2	81.0	(26.1-189.1)	Male	12	14.8	81.2	(41.9-141.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	49	51.0	96.1	(71.1-127.0)	Female	11	14.8	74.3	(37.0-132.9)
Female	63	51.0	123.6	(95.0-158.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	11	11.0	99.8	(49.8-178.6)
Male	11	9.7	113.0	(56.3-202.2)	Female	8	12.1	66.1	(28.4-130.2)
Female	4	2.7	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	169	143.5	117.8	(100.7-136.9)
Male	1	3.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	4	2.4	nc	(nc-nc)	Male	6	8.2	73.3	(26.8-159.6)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	6	5.5	109.3	(39.9-237.9)
Male	20	17.9	112.0	(68.4-173.0)	<b><u>Testis</u></b>				
Female	13	11.5	113.5	(60.4-194.1)	Male	3	5.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	6.1	nc	(nc-nc)	Male	10	6.1	163.3	(78.2-300.3)
Female	0	1.7	nc	(nc-nc)	Female	15	19.3	77.6	(43.4-128.1)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	17	11.9	142.9	(83.2-228.9)	Female	36	32.5	110.6	(77.5-153.2)
Female	13	9.9	131.8	(70.1-225.4)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	525	492.4	106.6	(97.7-116.1)
Male	6	8.8	68.2	(24.9-148.5)	Female	533	493.0	108.1	(99.1-117.7)
Female	3	3.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	68	67.7	100.5	(78.0-127.4)					
Female	71	68.8	103.2	(80.6-130.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chelsea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	29.9	76.9	(48.7-115.4)	Male	6	19.3	31.1	(11.4-67.7)
Female	12	10.4	114.9	(59.3-200.8)	Female	8	15.8	50.8	(21.9-100.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	6.3	143.3	(65.4-272.1)	Male	5	4.6	107.6	(34.7-251.2)
Female	6	5.1	117.8	(43.0-256.5)	Female	3	3.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	22	16.6	132.8	(83.2-201.1)
Female	85	100.4	84.7	(67.7-104.7)	Female	20	13.8	144.5	(88.2-223.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	5.1	157.7	(67.9-310.7)	Male	18	11.0	163.7	(96.9-258.7)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	40	41.7	95.9	(68.5-130.5)	Female	9	10.7	84.5	(38.6-160.4)
Female	44	38.4	114.5	(83.2-153.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	11	8.9	123.6	(61.6-221.1)
Male	13	7.5	172.3	(91.7-294.7)	Female	6	9.0	66.6	(24.3-144.9)
Female	2	2.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	89	106.7	83.4	(67.0-102.7)
Male	2	3.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	2.5	nc	(nc-nc)	Male	13	7.0	186.8	(99.4-319.5)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	12	4.3	278.2	(143.6-486.1)
Male	18	14.0	128.5	(76.1-203.1)	<b><u>Testis</u></b>				
Female	7	8.2	85.1	(34.1-175.3)	Male	1	6.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	11	4.7	236.2	(117.8-422.7)	Male	4	5.3	nc	(nc-nc)
Female	5	1.2	421.8	(135.9-984.4)	Female	17	16.2	105.0	(61.1-168.1)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	11	10.7	102.7	(51.2-183.8)	Female	22	21.8	101.1	(63.3-153.1)
Female	6	8.2	73.5	(26.8-160.0)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	401	396.7	101.1	(91.4-111.5)
Male	13	6.7	195.0	(103.7-333.4)	Female	361	362.1	99.7	(89.7-110.5)
Female	4	2.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	64	54.4	117.6	(90.6-150.2)					
Female	54	49.0	110.3	(82.9-143.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	4.4	225.0	(107.7-413.8)	Male	3	2.7	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	20	13.6	146.8	(89.7-226.8)	Female	2	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	6	6.3	95.1	(34.7-207.0)	Female	1	1.4	nc	(nc-nc)
Female	5	4.7	107.1	(34.5-250.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	1.4	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	Female	4	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	15	17.4	86.0	(48.1-141.9)
Male	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.5	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	1.4	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	71	59.8	118.7	(92.7-149.7)
Male	0	1.1	nc	(nc-nc)	Female	53	46.2	114.6	(85.9-150.0)
Female	0	0.3	nc	(nc-nc)	<b><u>Lung and Bronchus</u></b>				
Male	15	8.4	179.5	(100.4-296.1)	<b><u>Bladder, Urinary</u></b>				
Female	6	6.4	93.2	(34.0-202.8)	Male	10	4.4	225.0	(107.7-413.8)
<b><u>Lung and Bronchus</u></b>					Female	2	1.3	nc	(nc-nc)
Male	15	8.4	179.5	(100.4-296.1)	<b><u>Brain and Other Nervous System</u></b>				
Female	6	6.4	93.2	(34.0-202.8)	Male	2	0.8	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>					Female	1	0.6	nc	(nc-nc)
Male	15	8.4	179.5	(100.4-296.1)	<b><u>Breast</u></b>				
Female	6	6.4	93.2	(34.0-202.8)	Male	0	0.1	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>					Female	20	13.6	146.8	(89.7-226.8)
Male	15	8.4	179.5	(100.4-296.1)	<b><u>Cervix Uteri</u></b>				
Female	6	6.4	93.2	(34.0-202.8)	Female	0	0.6	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>					<b><u>Colon / Rectum</u></b>				
Male	15	8.4	179.5	(100.4-296.1)	Male	6	6.3	95.1	(34.7-207.0)
Female	6	6.4	93.2	(34.0-202.8)	Female	5	4.7	107.1	(34.5-250.0)
<b><u>Lung and Bronchus</u></b>					<b><u>Esophagus</u></b>				
Male	15	8.4	179.5	(100.4-296.1)	Male	0	1.2	nc	(nc-nc)
Female	6	6.4	93.2	(34.0-202.8)	Female	0	0.3	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>					<b><u>Hodgkin Lymphoma</u></b>				
Male	15	8.4	179.5	(100.4-296.1)	Male	0	0.3	nc	(nc-nc)
Female	6	6.4	93.2	(34.0-202.8)	Female	0	0.2	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>					<b><u>Kidney &amp; Renal Pelvis</u></b>				
Male	15	8.4	179.5	(100.4-296.1)	Male	3	2.1	nc	(nc-nc)
Female	6	6.4	93.2	(34.0-202.8)	Female	1	1.1	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>					<b><u>Larynx</u></b>				
Male	15	8.4	179.5	(100.4-296.1)	Male	1	0.7	nc	(nc-nc)
Female	6	6.4	93.2	(34.0-202.8)	Female	0	0.2	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>					<b><u>Leukemia</u></b>				
Male	15	8.4	179.5	(100.4-296.1)	Male	2	1.4	nc	(nc-nc)
Female	6	6.4	93.2	(34.0-202.8)	Female	1	0.9	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>					<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
Male	15	8.4	179.5	(100.4-296.1)	Male	0	1.1	nc	(nc-nc)
Female	6	6.4	93.2	(34.0-202.8)	Female	0	0.3	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	15	8.4	179.5	(100.4-296.1)	Male	15	8.4	179.5	(100.4-296.1)
Female	6	6.4	93.2	(34.0-202.8)	Female	6	6.4	93.2	(34.0-202.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	7	4.9	142.6	(57.1-293.8)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.0	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	1	0.1	nc	(nc-nc)	Female	1	5.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male				
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.4	nc	(nc-nc)	Male	11	19.7	55.9	(27.9-100.1)
Female	0	0.1	nc	(nc-nc)	Female	19	16.4	116.0	(69.8-181.1)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	2	2.7	nc	(nc-nc)					
Female	2	2.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	4	4.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	1.9	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	5	5.3	95.1	(30.7-222.0)
Male	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.4	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	14	18.0	77.6	(42.4-130.2)
Male	1	0.3	nc	(nc-nc)	Female	13	15.1	86.0	(45.7-147.0)
Female	0	0.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	1	2.4	nc	(nc-nc)					
Female	1	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	66	69.1	95.5	(73.9-121.5)	Male	30	40.5	74.1	(50.0-105.8)
Female	27	27.2	99.2	(65.3-144.3)	Female	28	33.7	83.1	(55.2-120.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	11.9	75.8	(34.6-143.9)	Male	10	10.5	94.9	(45.4-174.5)
Female	9	10.6	84.8	(38.7-161.0)	Female	9	8.6	104.2	(47.6-197.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	2.1	nc	(nc-nc)	Male	34	35.1	96.9	(67.1-135.4)
Female	239	241.9	98.8	(86.7-112.1)	Female	28	34.5	81.2	(54.0-117.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	9.7	61.8	(22.6-134.6)	Male	23	24.3	94.6	(59.9-141.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	72	94.8	76.0	(59.4-95.7)	Female	18	25.8	69.9	(41.4-110.4)
Female	102	98.5	103.6	(84.5-125.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	11	20.5	53.5	(26.7-95.8)
Male	15	17.4	86.3	(48.3-142.4)	Female	22	23.6	93.4	(58.5-141.4)
Female	2	5.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	224	247.8	90.4	(78.9-103.0)
Male	2	5.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	3	4.3	nc	(nc-nc)	Male	26	15.8	165.0	(107.8-241.8)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	11	10.8	101.9	(50.8-182.4)
Male	19	30.8	61.6	(37.1-96.3)	<b><u>Testis</u></b>				
Female	22	20.7	106.1	(66.5-160.7)	Male	7	8.2	85.0	(34.1-175.2)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	10	10.6	94.0	(45.0-172.9)	Male	3	9.7	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	Female	22	30.4	72.5	(45.4-109.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	17	21.9	77.7	(45.3-124.5)	Female	70	54.2	129.1	(100.7-163.2)
Female	14	18.4	76.3	(41.7-128.0)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	811	885.2	91.6	(85.4-98.1)
Male	14	15.0	93.4	(51.0-156.6)	Female	859	881.5	97.4	(91.0-104.2)
Female	8	5.7	139.4	(60.0-274.7)					
<b><u>Lung and Bronchus</u></b>									
Male	146	126.7	115.2	(97.3-135.5)					
Female	138	130.2	106.0	(89.1-125.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.6	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	5	4.7	106.1	(34.2-247.6)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	8	6.0	133.7	(57.6-263.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male				
Male	0	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	0	2.9	nc	(nc-nc)	Male	16	20.5	77.9	(44.5-126.5)
Female	2	2.3	nc	(nc-nc)	Female	12	16.2	73.9	(38.1-129.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	3	0.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	4	7.5	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	3.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	6	2.7	221.7	(80.9-482.5)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	0.6	nc	(nc-nc)	Male	9	9.1	98.9	(45.1-187.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney &amp; Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.1	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.4	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	Male	30	30.1	99.6	(67.2-142.2)
Female	0	0.5	nc	(nc-nc)	Female	28	25.9	108.1	(71.8-156.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	30	30.1	99.6	(67.2-142.2)
Female	0	0.2	nc	(nc-nc)	Female	28	25.9	108.1	(71.8-156.3)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	7	4.3	164.3	(65.8-338.6)	Male	30	30.1	99.6	(67.2-142.2)
Female	7	3.7	187.4	(75.1-386.2)	Female	28	25.9	108.1	(71.8-156.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	14.6	82.1	(42.4-143.4)	Male	9	9.2	98.1	(44.8-186.3)
Female	9	6.1	146.6	(66.9-278.3)	Female	6	8.1	74.2	(27.1-161.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	4	7.9	nc	(nc-nc)
Female	36	56.2	64.0	(44.8-88.6)	Female	5	7.9	63.4	(20.4-148.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.4	nc	(nc-nc)	Male	9	5.5	163.2	(74.5-309.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	29	20.5	141.8	(94.9-203.6)	Female	6	6.0	100.6	(36.7-218.9)
Female	24	22.6	106.4	(68.2-158.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	4.4	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	37	53.9	68.6	(48.3-94.6)
Male	1	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	5	3.4	147.9	(47.7-345.1)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	2.5	nc	(nc-nc)
Male	9	6.9	130.3	(59.5-247.4)	<b><u>Testis</u></b>				
Female	8	4.7	170.0	(73.2-334.9)	Male	1	2.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	6	7.6	78.9	(28.8-171.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	4.9	nc	(nc-nc)	Female	8	12.4	64.6	(27.8-127.3)
Female	6	4.3	139.8	(51.1-304.3)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	182	193.7	94.0	(80.8-108.6)
Male	3	3.3	nc	(nc-nc)	Female	175	203.3	86.1	(73.8-99.8)
Female	1	1.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	29	27.0	107.2	(71.8-154.0)					
Female	23	29.0	79.4	(50.3-119.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	8.8	147.0	(78.2-251.4)	Male	14	5.5	256.5	(140.1-430.4)
Female	4	3.3	nc	(nc-nc)	Female	18	4.3	414.1	(245.3-654.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.6	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.7	107.0	(34.5-249.8)
Female	31	32.4	95.6	(65.0-135.7)	Female	3	4.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	13	12.5	103.8	(55.2-177.4)	Female	7	3.4	208.6	(83.6-429.7)
Female	15	11.8	126.7	(70.9-209.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	2.7	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	42	34.4	122.1	(88.0-165.1)
Male	2	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.3	nc	(nc-nc)
Male	6	4.2	141.2	(51.6-307.4)	<b><u>Testis</u></b>				
Female	1	2.6	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	8	4.1	193.7	(83.4-381.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	2.9	209.2	(76.4-455.5)	Female	10	7.3	137.3	(65.7-252.5)
Female	1	2.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	159	118.7	134.0	(114.0-156.5)
Male	1	2.1	nc	(nc-nc)	Female	124	112.1	110.6	(92.0-131.9)
Female	2	0.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	20	16.6	120.5	(73.6-186.2)					
Female	12	15.9	75.4	(38.9-131.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	7	6.7	104.3	(41.8-214.9)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	3.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	3	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	8.5	70.8	(25.8-154.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male				
Male	0	1.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	0.7	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.5	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	3	4.2	nc	(nc-nc)	Male	19	29.8	63.7	(38.3-99.5)
Female	6	3.1	196.4	(71.7-427.6)	Female	29	22.4	129.2	(86.5-185.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	23.4	72.7	(42.3-116.3)	Male	23	14.1	162.8	(103.2-244.3)
Female	11	8.0	138.0	(68.8-246.9)	Female	20	10.1	197.4	(120.5-304.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	4.1	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	5	3.2	156.3	(50.4-364.8)	Female	4	2.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	14	12.1	115.6	(63.2-194.0)
Female	113	76.6	147.6	(121.6-177.4)	Female	11	10.2	108.1	(53.9-193.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.0	nc	(nc-nc)	Male	4	8.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	20	32.6	61.3	(37.4-94.7)	Female	12	8.0	150.3	(77.6-262.6)
Female	34	29.3	116.2	(80.4-162.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	7.1	nc	(nc-nc)
Male	0	6.0	nc	(nc-nc)	Female	9	6.9	129.9	(59.3-246.6)
Female	3	1.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	91	87.2	104.4	(84.1-128.2)
Male	4	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	2	5.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	3.2	nc	(nc-nc)
Male	8	10.8	74.0	(31.8-145.7)	<b><u>Testis</u></b>				
Female	11	6.2	177.0	(88.3-316.8)	Male	2	2.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	3.7	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	6	9.2	65.0	(23.7-141.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	12	7.4	162.4	(83.8-283.7)	Female	21	17.2	122.0	(75.5-186.5)
Female	6	5.4	110.4	(40.3-240.3)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	256	306.0	83.6	(73.7-94.5)
Male	2	5.3	nc	(nc-nc)	Female	312	267.6	116.6	(104.0-130.3)
Female	1	1.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	26	43.2	60.2	(39.3-88.1)					
Female	19	37.9	50.1	(30.1-78.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.9	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	7	7.4	94.6	(37.9-195.0)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	2.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.5	nc	(nc-nc)	Male	3	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	8.0	125.5	(60.1-230.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male				
Male	2	1.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	1	3.6	nc	(nc-nc)	Male	23	27.2	84.7	(53.7-127.1)
Female	0	3.0	nc	(nc-nc)	Female	15	23.6	63.6	(35.6-104.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	3.8	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	6	4.0	148.2	(54.1-322.7)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male				
Male	2	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.2	nc	(nc-nc)	Male	15	13.9	107.6	(60.2-177.5)
Female	0	0.1	nc	(nc-nc)	Female	14	12.8	109.4	(59.8-183.6)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	4	1.9	nc	(nc-nc)	Male	15	13.9	107.6	(60.2-177.5)
Female	3	1.7	nc	(nc-nc)	Female	14	12.8	109.4	(59.8-183.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	8.2	170.9	(93.4-286.8)	Male	11	4.9	222.7	(111.0-398.5)
Female	4	3.4	nc	(nc-nc)	Female	5	4.2	118.0	(38.0-275.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	5	1.3	376.9	(121.5-879.5)	Female	0	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.3	164.4	(65.9-338.8)
Female	25	31.1	80.4	(52.0-118.6)	Female	2	4.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	16	11.4	139.8	(79.9-227.1)	Female	3	3.3	nc	(nc-nc)
Female	25	12.4	201.9	(130.6-298.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	2.5	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	31	30.6	101.3	(68.8-143.9)
Male	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.4	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	2.6	nc	(nc-nc)	Male	4	0.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	2.6	nc	(nc-nc)	Female	6	6.9	86.6	(31.6-188.5)
Female	1	2.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	122	107.5	113.5	(94.2-135.5)
Male	4	1.9	nc	(nc-nc)	Female	116	111.3	104.2	(86.1-125.0)
Female	1	0.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	11	15.2	72.2	(36.0-129.3)					
Female	15	16.1	93.0	(52.0-153.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	43	32.7	131.5	(95.2-177.2)	Male	31	19.5	159.2	(108.2-226.0)
Female	14	12.9	108.2	(59.1-181.5)	Female	18	16.3	110.3	(65.3-174.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	5.7	106.0	(38.7-230.7)	Male	6	5.1	118.8	(43.4-258.5)
Female	8	5.1	156.6	(67.4-308.5)	Female	1	4.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	22	16.7	131.4	(82.3-199.0)
Female	122	119.0	102.6	(85.2-122.5)	Female	19	16.4	115.6	(69.6-180.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.8	nc	(nc-nc)	Male	11	11.9	92.2	(46.0-165.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	53	45.2	117.1	(87.7-153.2)	Female	15	12.5	119.6	(66.9-197.3)
Female	48	47.3	101.6	(74.9-134.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	14	9.8	142.7	(78.0-239.5)
Male	5	8.4	59.7	(19.3-139.4)	Female	12	11.2	106.9	(55.2-186.8)
Female	4	2.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	133	121.3	109.7	(91.8-130.0)
Male	4	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	5	1.9	256.6	(82.7-598.9)	Male	10	7.5	133.9	(64.1-246.2)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	5.2	nc	(nc-nc)
Male	17	14.9	114.0	(66.4-182.6)	<b><u>Testis</u></b>				
Female	7	9.9	70.9	(28.4-146.0)	Male	8	3.6	222.4	(95.8-438.3)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	5.2	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	9	14.9	60.4	(27.6-114.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	15	10.3	145.7	(81.5-240.4)	Female	32	26.5	120.6	(82.5-170.3)
Female	8	8.8	91.1	(39.2-179.4)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	481	425.1	113.1	(103.3-123.7)
Male	7	7.3	95.8	(38.4-197.5)	Female	464	425.7	109.0	(99.3-119.4)
Female	2	2.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	53	60.4	87.7	(65.7-114.8)					
Female	66	61.3	107.6	(83.2-137.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dartmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	41	37.1	110.5	(79.3-149.8)	Male	12	22.6	53.0	(27.4-92.6)
Female	20	13.9	144.3	(88.1-222.9)	Female	17	18.0	94.6	(55.0-151.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	6.7	104.9	(42.0-216.1)	Male	8	5.8	138.6	(59.7-273.2)
Female	6	5.6	107.5	(39.3-234.0)	Female	4	4.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	18	19.5	92.3	(54.7-145.9)
Female	141	129.1	109.2	(91.9-128.8)	Female	15	17.8	84.4	(47.2-139.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	5.3	114.1	(41.7-248.3)	Male	20	13.9	144.0	(87.9-222.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	64	51.8	123.5	(95.1-157.7)	Female	12	13.7	87.8	(45.3-153.3)
Female	46	50.6	90.9	(66.5-121.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	11	11.2	98.3	(49.0-175.9)
Male	11	9.6	115.0	(57.3-205.7)	Female	14	12.0	116.3	(63.6-195.2)
Female	1	2.7	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	159	137.4	115.7	(98.4-135.2)
Male	0	3.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	2.4	nc	(nc-nc)	Male	13	8.5	152.3	(81.0-260.5)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	8	5.5	144.6	(62.3-285.0)
Male	27	17.1	157.5	(103.8-229.1)	<b><u>Testis</u></b>				
Female	7	10.7	65.3	(26.2-134.6)	Male	1	5.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	6	5.9	101.6	(37.1-221.2)	Male	8	5.6	141.7	(61.0-279.1)
Female	3	1.6	nc	(nc-nc)	Female	16	16.7	96.0	(54.8-155.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	17	12.0	141.4	(82.3-226.4)	Female	40	28.9	138.6	(99.0-188.8)
Female	7	9.5	74.1	(29.7-152.6)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	520	487.7	106.6	(97.7-116.2)
Male	6	8.4	71.0	(25.9-154.6)	Female	462	461.1	100.2	(91.3-109.8)
Female	0	2.9	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	67	68.4	97.9	(75.9-124.4)					
Female	55	66.2	83.1	(62.6-108.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dedham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	32	30.5	104.9	(71.7-148.1)	Male	17	18.2	93.6	(54.5-149.9)
Female	15	11.3	132.6	(74.2-218.7)	Female	19	14.4	131.8	(79.3-205.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	5.3	207.0	(103.2-370.4)	Male	7	4.7	149.2	(59.8-307.5)
Female	2	4.5	nc	(nc-nc)	Female	5	3.6	139.7	(45.0-326.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.0	nc	(nc-nc)	Male	22	15.6	140.8	(88.2-213.2)
Female	124	105.2	117.9	(98.1-140.6)	Female	13	14.3	90.6	(48.2-154.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.3	nc	(nc-nc)	Male	11	11.0	100.2	(50.0-179.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	36	42.0	85.6	(60.0-118.5)	Female	10	11.0	90.6	(43.4-166.6)
Female	37	40.7	90.9	(64.0-125.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	9.1	65.8	(24.0-143.3)
Male	9	7.8	116.1	(53.0-220.4)	Female	4	9.7	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	137	111.4	123.0	(103.2-145.4)
Male	0	2.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.7	nc	(nc-nc)	Male	8	7.0	114.7	(49.4-226.0)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	4.4	nc	(nc-nc)
Male	11	13.8	79.5	(39.6-142.3)	<b><u>Testis</u></b>				
Female	13	8.8	148.3	(78.9-253.6)	Male	5	3.6	138.6	(44.7-323.5)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	4.8	104.7	(33.8-244.4)	Male	8	4.4	182.2	(78.5-359.1)
Female	2	1.3	nc	(nc-nc)	Female	27	13.3	203.0	(133.8-295.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	9.7	103.5	(49.6-190.4)	Female	24	23.7	101.2	(64.8-150.5)
Female	11	7.7	143.7	(71.6-257.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	424	394.6	107.4	(97.5-118.2)
Male	7	6.7	103.9	(41.6-214.0)	Female	414	374.3	110.6	(100.2-121.8)
Female	1	2.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	46	56.2	81.9	(59.9-109.2)					
Female	62	54.5	113.8	(87.2-145.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	5.8	103.4	(37.8-225.1)	Male	9	3.7	243.9	(111.3-463.1)
Female	5	2.0	250.2	(80.6-583.8)	Female	0	2.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	4	0.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	22	20.9	105.3	(65.9-159.4)	Female	2	2.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.9	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	7	8.3	84.2	(33.7-173.4)	Female	3	2.2	nc	(nc-nc)
Female	2	7.3	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	1	1.6	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	19	22.8	83.2	(50.1-129.9)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	1	2.9	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	4	1.9	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.4	nc	(nc-nc)	Female	7	4.7	148.0	(59.3-305.0)
Female	0	0.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	6	10.9	55.2	(20.2-120.3)	Male	71	79.0	89.8	(70.1-113.3)
Female	6	9.8	61.3	(22.4-133.4)	Female	65	70.9	91.7	(70.8-116.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	45	34.0	132.3	(96.5-177.1)	Male	38	17.5	217.7	(154.1-298.9)
Female	16	11.7	136.3	(77.9-221.4)	Female	18	12.6	143.3	(84.9-226.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	4.6	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
Female	5	4.0	126.5	(40.8-295.2)	Female	3	3.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	8	15.4	52.0	(22.4-102.6)
Female	109	96.3	113.2	(92.9-136.5)	Female	9	14.3	63.1	(28.8-119.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	3.3	nc	(nc-nc)	Male	15	10.1	148.9	(83.3-245.7)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	51	44.6	114.5	(85.2-150.5)	Female	16	10.4	154.5	(88.2-250.9)
Female	43	41.7	103.2	(74.7-139.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	9	9.8	91.8	(41.9-174.3)
Male	7	8.0	87.4	(35.0-180.1)	Female	10	10.1	99.0	(47.4-182.1)
Female	2	2.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	168	115.2	145.8	(124.6-169.6)
Male	2	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	2	7.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	4.5	nc	(nc-nc)
Male	15	13.5	111.0	(62.1-183.1)	<b><u>Testis</u></b>				
Female	8	8.6	92.7	(39.9-182.7)	Male	2	2.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	6	4.9	123.2	(45.0-268.1)	Male	5	3.4	145.8	(47.0-340.3)
Female	0	1.3	nc	(nc-nc)	Female	6	10.1	59.6	(21.7-129.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	12	9.7	124.1	(64.0-216.8)	Female	26	22.1	117.7	(76.9-172.5)
Female	16	7.3	219.6	(125.4-356.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	499	406.8	122.7	(112.1-133.9)
Male	10	6.5	153.7	(73.6-282.7)	Female	390	359.1	108.6	(98.1-119.9)
Female	1	2.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	54	61.3	88.1	(66.2-115.0)					
Female	60	56.4	106.4	(81.2-137.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	7.1	85.1	(31.1-185.2)	Male	1	4.5	nc	(nc-nc)
Female	6	2.6	234.3	(85.6-510.0)	Female	1	3.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	8	3.9	206.9	(89.1-407.7)
Female	24	25.9	92.8	(59.4-138.1)	Female	4	3.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	14	10.1	138.8	(75.8-232.9)	Female	0	2.7	nc	(nc-nc)
Female	7	9.3	75.0	(30.0-154.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	2.2	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	19	27.3	69.6	(41.9-108.7)
Male	2	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	5	1.0	492.2	(158.6-1148.5)
Male	7	3.4	203.2	(81.4-418.8)	<b><u>Testis</u></b>				
Female	4	2.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	2.4	nc	(nc-nc)	Female	3	5.8	nc	(nc-nc)
Female	4	1.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	90	95.8	93.9	(75.5-115.5)
Male	0	1.7	nc	(nc-nc)	Female	95	89.5	106.1	(85.9-129.8)
Female	2	0.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	13	13.2	98.8	(52.5-168.9)					
Female	15	12.4	121.4	(67.9-200.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	5.4	110.5	(40.4-240.6)	Male	4	4.1	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	26	22.6	115.2	(75.3-168.9)	Female	2	2.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	7	8.2	85.7	(34.3-176.5)	Female	2	2.3	nc	(nc-nc)
Female	8	7.2	111.8	(48.1-220.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	13	21.3	61.1	(32.5-104.4)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	3.0	nc	(nc-nc)	Female	4	4.8	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	61	78.8	77.4	(59.2-99.5)
Female	0	0.2	nc	(nc-nc)	Female	76	75.1	101.2	(79.7-126.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	2.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
Female	3	1.6	nc	(nc-nc)	Male	61	78.8	77.4	(59.2-99.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.5	nc	(nc-nc)	Female	76	75.1	101.2	(79.7-126.6)
Female	0	0.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	10.1	79.0	(34.0-155.7)	Male	61	78.8	77.4	(59.2-99.5)
Female	11	9.3	118.2	(58.9-211.5)	Female	76	75.1	101.2	(79.7-126.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dover

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	6.3	nc	(nc-nc)	Male	8	4.1	196.2	(84.5-386.6)
Female	2	1.9	nc	(nc-nc)	Female	9	3.0	302.8	(138.2-574.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	28	22.3	125.7	(83.5-181.7)	Female	2	2.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	7	9.1	76.7	(30.7-158.1)	Female	3	2.2	nc	(nc-nc)
Female	6	6.7	89.9	(32.8-195.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	33	25.7	128.4	(88.4-180.4)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	3.2	nc	(nc-nc)	Female	4	5.1	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	79	87.4	90.4	(71.5-112.6)
Female	0	0.3	nc	(nc-nc)	Female	80	71.9	111.2	(88.2-138.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	2.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
Female	0	1.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
Female	1	0.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	12.0	66.8	(28.8-131.7)	<b><u>All Sites / Types</u></b>				
Female	7	9.7	72.3	(29.0-149.0)	<b><u>All Sites / Types</u></b>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dracut

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	36	27.4	131.6	(92.1-182.2)	Male	15	18.1	82.9	(46.4-136.8)
Female	14	10.2	136.9	(74.8-229.8)	Female	14	15.2	91.9	(50.2-154.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	5.7	140.3	(60.4-276.4)	Male	1	4.4	nc	(nc-nc)
Female	3	4.7	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	12	15.4	78.1	(40.3-136.5)
Female	114	106.4	107.1	(88.4-128.7)	Female	21	13.5	155.1	(96.0-237.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	4.9	nc	(nc-nc)	Male	18	11.3	159.8	(94.7-252.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	46	39.3	117.1	(85.7-156.2)	Female	11	10.9	100.7	(50.2-180.2)
Female	42	36.2	115.9	(83.5-156.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	12	8.4	142.5	(73.5-248.9)
Male	8	7.4	107.8	(46.4-212.5)	Female	8	8.7	91.9	(39.6-181.1)
Female	6	2.0	304.6	(111.2-663.1)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	111	107.7	103.1	(84.8-124.1)
Male	1	2.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	2.1	nc	(nc-nc)	Male	5	6.3	79.0	(25.5-184.5)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	7	3.9	181.5	(72.7-374.0)
Male	15	13.8	108.9	(60.9-179.6)	<b><u>Testis</u></b>				
Female	14	8.5	164.2	(89.7-275.4)	Male	7	4.6	150.9	(60.4-310.9)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	6	4.6	129.9	(47.4-282.6)	Male	7	4.9	141.8	(56.8-292.1)
Female	3	1.3	nc	(nc-nc)	Female	25	15.6	160.1	(103.6-236.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	9.4	106.2	(50.8-195.2)	Female	26	23.6	110.0	(71.8-161.1)
Female	10	7.4	135.9	(65.1-250.0)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	405	378.7	106.9	(96.8-117.9)
Male	7	6.8	103.3	(41.4-212.9)	Female	431	364.4	118.3	(107.4-130.0)
Female	2	2.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	59	52.1	113.3	(86.2-146.1)					
Female	63	51.0	123.5	(94.9-158.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dudley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	11.1	nc	(nc-nc)	Male	4	7.0	nc	(nc-nc)
Female	5	3.9	128.2	(41.3-299.2)	Female	6	5.6	106.9	(39.1-232.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	6	6.0	99.4	(36.3-216.5)
Female	39	39.0	100.0	(71.1-136.7)	Female	4	5.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	7	4.3	161.2	(64.6-332.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	19	15.7	121.2	(72.9-189.2)	Female	6	4.1	147.2	(53.8-320.4)
Female	15	14.2	105.8	(59.2-174.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	3.4	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	Female	2	3.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	36	41.9	85.8	(60.1-118.8)
Male	3	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.5	nc	(nc-nc)
Male	6	5.3	113.0	(41.3-246.0)	<b><u>Testis</u></b>				
Female	4	3.2	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	7	5.6	124.9	(50.0-257.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	3.7	nc	(nc-nc)	Female	6	8.6	69.7	(25.4-151.7)
Female	1	2.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	131	149.0	87.9	(73.5-104.3)
Male	2	2.6	nc	(nc-nc)	Female	129	136.1	94.8	(79.1-112.6)
Female	1	0.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	19	20.6	92.3	(55.5-144.1)					
Female	17	18.9	89.9	(52.3-143.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	17	10.3	165.8	(96.5-265.4)	Female	1	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	3.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	9	10.7	84.4	(38.5-160.3)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	2	1.4	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	1	0.9	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.7	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	2	4.7	nc	(nc-nc)	Male	27	36.3	74.4	(49.0-108.2)
Female	2	3.9	nc	(nc-nc)	Female	37	31.9	116.1	(81.7-160.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	15.8	56.9	(26.0-108.1)	Male	28	10.3	271.4	(180.3-392.3)
Female	6	5.9	101.4	(37.0-220.7)	Female	20	8.5	236.6	(144.5-365.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.2	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	4	2.6	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	11	8.8	125.5	(62.6-224.6)
Female	67	62.3	107.5	(83.3-136.6)	Female	11	7.9	140.1	(69.8-250.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.6	nc	(nc-nc)	Male	4	6.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	21	22.9	91.5	(56.6-139.9)	Female	3	6.4	nc	(nc-nc)
Female	21	22.1	95.2	(58.9-145.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	5.0	100.8	(32.5-235.3)
Male	6	4.4	136.1	(49.7-296.3)	Female	5	5.2	96.9	(31.2-226.1)
Female	0	1.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	102	64.2	158.8	(129.5-192.7)
Male	2	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	3	1.0	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	2.4	nc	(nc-nc)
Male	10	8.0	125.2	(59.9-230.2)	<b><u>Testis</u></b>				
Female	4	4.8	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	2.8	nc	(nc-nc)	Male	6	2.7	225.6	(82.4-491.1)
Female	0	0.7	nc	(nc-nc)	Female	9	8.2	109.1	(49.8-207.1)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	5.3	169.1	(77.2-321.1)	Female	13	13.9	93.5	(49.8-159.9)
Female	5	4.3	117.3	(37.8-273.8)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	256	219.8	116.5	(102.7-131.7)
Male	1	4.1	nc	(nc-nc)	Female	238	210.9	112.9	(99.0-128.1)
Female	4	1.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	18	29.8	60.3	(35.7-95.4)					
Female	30	28.3	106.1	(71.6-151.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	12.3	89.6	(44.7-160.4)	Male	10	8.4	119.7	(57.3-220.1)
Female	0	4.5	nc	(nc-nc)	Female	15	7.0	212.9	(119.0-351.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.7	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.1	84.8	(31.0-184.6)
Female	51	48.9	104.3	(77.6-137.1)	Female	10	6.1	164.1	(78.6-301.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.3	nc	(nc-nc)	Male	8	5.3	150.3	(64.7-296.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	18	17.9	100.6	(59.6-159.1)	Female	8	5.0	159.2	(68.6-313.7)
Female	25	16.4	152.5	(98.6-225.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	3	3.4	nc	(nc-nc)	Male	57	49.7	114.7	(86.9-148.6)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	5	2.1	232.8	(75.0-543.3)
Female	2	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	6.4	78.6	(25.3-183.5)	Female	11	10.9	100.7	(50.2-180.2)
Female	5	3.8	131.7	(42.4-307.3)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	172	173.4	99.2	(84.9-115.2)
Female	2	0.6	nc	(nc-nc)	Female	182	165.5	110.0	(94.6-127.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	4.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Lung and Bronchus</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	26	23.4	111.0	(72.5-162.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	19	22.2	85.8	(51.6-134.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	2.4	245.5	(89.7-534.4)	Male	1	1.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	7	8.2	85.6	(34.3-176.4)	Female	1	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	3.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.7	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	4	9.5	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.3	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	0.8	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	35	33.1	105.8	(73.7-147.2)
Male	0	0.6	nc	(nc-nc)	Female	22	28.1	78.3	(49.1-118.6)
Female	0	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	8	4.6	174.6	(75.2-344.1)					
Female	4	3.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	20.1	114.2	(72.4-171.4)	Male	13	11.8	110.6	(58.8-189.1)
Female	7	8.0	87.7	(35.1-180.7)	Female	9	9.5	94.3	(43.0-178.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	3.4	176.3	(64.4-383.8)	Male	2	3.1	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	16	10.2	157.4	(89.9-255.6)
Female	90	70.2	128.3	(103.2-157.7)	Female	12	10.0	120.0	(61.9-209.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.7	nc	(nc-nc)	Male	4	7.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	21	27.7	75.8	(46.9-115.9)	Female	11	7.5	147.6	(73.6-264.0)
Female	19	29.5	64.4	(38.8-100.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	6.0	nc	(nc-nc)
Male	4	5.1	nc	(nc-nc)	Female	7	7.0	100.2	(40.1-206.4)
Female	0	1.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	81	73.1	110.8	(88.0-137.7)
Male	3	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	5	4.6	108.7	(35.0-253.6)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	3.3	nc	(nc-nc)
Male	7	9.0	77.4	(31.0-159.5)	<b><u>Testis</u></b>				
Female	4	5.9	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	3.1	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	2	8.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	6.3	127.1	(54.7-250.5)	Female	21	15.4	136.1	(84.2-208.1)
Female	4	5.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	245	258.4	94.8	(83.3-107.5)
Male	2	4.4	nc	(nc-nc)	Female	249	255.6	97.4	(85.7-110.3)
Female	2	1.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	19	37.0	51.3	(30.9-80.1)					
Female	21	37.2	56.5	(35.0-86.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Eastham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	11.6	164.3	(98.9-256.6)	Male	13	6.0	215.6	(114.7-368.8)
Female	5	3.5	141.6	(45.6-330.4)	Female	5	4.0	124.8	(40.2-291.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	2	5.3	nc	(nc-nc)
Female	35	30.5	114.7	(79.9-159.5)	Female	2	4.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	14	15.3	91.8	(50.1-154.0)	Female	4	3.2	nc	(nc-nc)
Female	12	12.2	98.0	(50.6-171.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	3.3	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	58	39.7	146.1	(110.9-188.9)
Male	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.3	nc	(nc-nc)
Male	3	4.7	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	3	2.7	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	3.3	150.7	(48.6-351.7)	Female	9	7.0	128.0	(58.4-243.1)
Female	1	2.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	156	140.0	111.5	(94.6-130.4)
Male	0	2.3	nc	(nc-nc)	Female	107	111.0	96.4	(79.0-116.5)
Female	0	0.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	11	21.1	52.2	(26.0-93.4)					
Female	11	17.4	63.2	(31.5-113.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	18.1	77.5	(42.3-130.0)	Male	9	11.3	79.7	(36.4-151.3)
Female	5	7.0	71.1	(22.9-165.9)	Female	6	9.6	62.3	(22.8-135.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.4	148.7	(47.9-347.1)	Male	2	2.8	nc	(nc-nc)
Female	5	2.9	171.2	(55.2-399.4)	Female	4	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	4	9.7	nc	(nc-nc)
Female	72	67.4	106.9	(83.6-134.6)	Female	9	9.2	98.4	(44.9-186.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.9	nc	(nc-nc)	Male	13	6.9	188.2	(100.1-321.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	32	25.5	125.5	(85.8-177.1)	Female	8	7.1	113.0	(48.7-222.7)
Female	17	25.9	65.7	(38.2-105.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	5.4	nc	(nc-nc)
Male	6	4.7	128.5	(46.9-279.8)	Female	10	6.1	163.3	(78.2-300.3)
Female	2	1.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	66	65.8	100.4	(77.6-127.7)
Male	1	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	2.8	nc	(nc-nc)
Male	11	8.5	130.0	(64.8-232.7)	<b><u>Testis</u></b>				
Female	4	5.5	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	2.9	nc	(nc-nc)	Male	0	2.9	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	11	9.2	119.3	(59.5-213.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	5.9	nc	(nc-nc)	Female	10	14.9	67.3	(32.2-123.7)
Female	2	4.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	241	238.1	101.2	(88.9-114.9)
Male	4	4.2	nc	(nc-nc)	Female	216	238.6	90.5	(78.8-103.4)
Female	2	1.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	38	33.1	114.9	(81.3-157.7)					
Female	23	33.5	68.6	(43.5-103.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Easton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	19.1	109.7	(67.9-167.6)	Male	25	13.5	185.7	(120.2-274.2)
Female	2	6.8	nc	(nc-nc)	Female	14	11.4	122.7	(67.0-205.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	4.3	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	5	3.5	142.6	(45.9-332.7)	Female	1	2.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	16	11.3	141.1	(80.6-229.2)
Female	94	78.2	120.3	(97.2-147.2)	Female	6	9.4	64.1	(23.4-139.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	3.8	186.2	(74.6-383.6)	Male	5	8.7	57.2	(18.4-133.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	31	28.3	109.5	(74.4-155.4)	Female	6	8.0	75.2	(27.5-163.6)
Female	23	24.6	93.5	(59.2-140.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	6.1	99.1	(36.2-215.7)
Male	6	5.4	110.2	(40.2-239.8)	Female	8	5.8	138.4	(59.6-272.6)
Female	2	1.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	100	79.7	125.4	(102.0-152.6)
Male	5	2.1	242.5	(78.2-566.0)	<b><u>Stomach</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	2.6	nc	(nc-nc)
Male	13	10.1	128.4	(68.3-219.5)	<b><u>Testis</u></b>				
Female	6	5.9	101.7	(37.2-221.5)	Male	3	3.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	13	12.3	105.5	(56.1-180.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	7	6.9	101.9	(40.8-210.1)	Female	19	17.4	109.5	(65.9-171.0)
Female	5	5.1	97.2	(31.3-226.8)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	306	276.3	110.7	(98.7-123.9)
Male	5	5.1	97.7	(31.5-227.9)	Female	279	258.6	107.9	(95.6-121.3)
Female	2	1.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	34	36.6	93.0	(64.4-130.0)					
Female	38	33.5	113.5	(80.3-155.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	4.5	112.1	(36.1-261.7)	Male	4	3.0	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	23	15.9	144.7	(91.7-217.2)	Female	3	2.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	6.5	nc	(nc-nc)	Female	4	1.6	nc	(nc-nc)
Female	6	5.3	113.2	(41.3-246.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	1.4	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	4	1.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	17	18.4	92.3	(53.8-147.8)
Male	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.6	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.5	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	55	62.8	87.6	(66.0-114.0)
Male	2	1.2	nc	(nc-nc)	Female	61	53.6	113.9	(87.1-146.3)
Female	0	0.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	6	8.6	70.0	(25.6-152.4)					
Female	4	7.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.5	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	4	7.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	3.4	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Female	5	2.5	200.7	(64.7-468.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	5	9.1	54.9	(17.7-128.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney &amp; Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.1	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Male	14	31.3	44.7	(24.4-75.1)
Female	0	0.1	nc	(nc-nc)	Female	21	24.4	86.0	(53.2-131.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.5	nc	(nc-nc)	Male	14	31.3	44.7	(24.4-75.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	21	24.4	86.0	(53.2-131.4)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	4.5	nc	(nc-nc)	Male	14	31.3	44.7	(24.4-75.1)
Female	3	3.6	nc	(nc-nc)	Female	21	24.4	86.0	(53.2-131.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.9	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	5	6.1	81.8	(26.4-190.9)	Female	2	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	6	7.3	82.6	(30.2-179.8)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Kidney &amp; Renal Pelvis</u>					Female	1	0.2	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.6	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	19	25.5	74.5	(44.8-116.4)
Male	0	0.4	nc	(nc-nc)	Female	20	21.1	94.9	(58.0-146.6)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	3.5	nc	(nc-nc)					
Female	4	2.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Essex

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.9	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	16	13.5	118.8	(67.9-193.0)	Female	3	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	5.6	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
Female	7	4.7	149.2	(59.8-307.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	1.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	26	15.4	168.9	(110.3-247.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male				
Male	1	1.9	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	1.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.0	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	4	7.4	nc	(nc-nc)	Male	56	53.4	104.8	(79.2-136.1)
Female	9	6.4	141.3	(64.5-268.2)	Female	54	45.9	117.6	(88.4-153.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	53	40.5	130.9	(98.1-171.3)	Male	16	24.7	64.8	(37.0-105.2)
Female	13	16.1	80.8	(43.0-138.2)	Female	14	21.6	64.8	(35.4-108.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	13	7.5	173.9	(92.5-297.4)	Male	5	6.2	80.4	(25.9-187.5)
Female	4	6.7	nc	(nc-nc)	Female	1	5.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	19	21.2	89.5	(53.9-139.8)
Female	123	149.1	82.5	(68.6-98.4)	Female	26	20.7	125.7	(82.1-184.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	6.6	91.5	(33.4-199.1)	Male	16	14.5	110.6	(63.2-179.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	81	55.8	145.2	(115.3-180.5)	Female	13	15.8	82.5	(43.9-141.0)
Female	60	58.2	103.1	(78.7-132.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	12.0	49.8	(18.2-108.5)
Male	13	10.2	127.3	(67.7-217.6)	Female	16	13.9	115.5	(65.9-187.5)
Female	2	3.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	126	146.7	85.9	(71.5-102.3)
Male	4	3.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	2.9	nc	(nc-nc)	Male	13	9.3	140.4	(74.7-240.0)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	12	6.4	187.7	(96.9-327.8)
Male	21	18.4	114.1	(70.6-174.4)	<b><u>Testis</u></b>				
Female	15	12.5	120.3	(67.3-198.4)	Male	5	6.3	79.8	(25.7-186.2)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	6	6.3	95.1	(34.7-206.9)	Male	4	6.3	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	20	20.7	96.8	(59.1-149.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	12	13.3	90.4	(46.7-157.9)	Female	25	33.2	75.4	(48.8-111.3)
Female	9	11.2	80.4	(36.7-152.5)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	539	527.3	102.2	(93.8-111.2)
Male	12	8.9	135.2	(69.8-236.1)	Female	524	536.5	97.7	(89.5-106.4)
Female	7	3.4	204.3	(81.8-420.9)					
<b><u>Lung and Bronchus</u></b>									
Male	84	74.4	112.8	(90.0-139.7)					
Female	101	77.0	131.2	(106.9-159.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fairhaven

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	31	22.7	136.8	(92.9-194.2)	Male	14	13.0	107.4	(58.6-180.1)
Female	9	9.3	96.5	(44.0-183.3)	Female	11	11.0	100.4	(50.0-179.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.7	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	11	11.3	97.2	(48.4-173.9)
Female	75	79.4	94.5	(74.3-118.4)	Female	11	11.7	94.4	(47.1-169.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.1	nc	(nc-nc)	Male	9	7.8	115.8	(52.8-219.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	24	30.9	77.7	(49.8-115.7)	Female	10	8.5	117.1	(56.1-215.5)
Female	20	34.8	57.5	(35.1-88.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	6.7	nc	(nc-nc)
Male	6	5.6	107.0	(39.1-233.0)	Female	10	8.2	122.1	(58.4-224.5)
Female	2	1.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	107	79.3	134.9	(110.6-163.0)
Male	2	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	10	5.2	192.8	(92.3-354.6)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	3.9	nc	(nc-nc)
Male	13	9.9	131.6	(70.0-225.0)	<b><u>Testis</u></b>				
Female	7	6.8	103.1	(41.3-212.5)	Male	3	2.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	3.4	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	4	9.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	7.0	127.9	(58.4-242.8)	Female	15	17.5	85.8	(48.0-141.5)
Female	4	6.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	313	285.3	109.7	(97.9-122.6)
Male	1	4.8	nc	(nc-nc)	Female	268	294.2	91.1	(80.5-102.7)
Female	2	2.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	37	40.9	90.4	(63.7-124.6)					
Female	45	42.8	105.1	(76.7-140.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	116	104.0	111.6	(92.2-133.8)	Male	28	61.4	45.6	(30.3-66.0)
Female	51	45.2	112.8	(84.0-148.3)	Female	25	55.7	44.9	(29.0-66.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	16	18.4	87.0	(49.7-141.2)	Male	15	15.8	94.8	(53.0-156.3)
Female	21	17.7	118.8	(73.5-181.6)	Female	15	14.3	104.9	(58.7-173.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	3.2	nc	(nc-nc)	Male	50	53.3	93.9	(69.7-123.8)
Female	340	386.8	87.9	(78.8-97.8)	Female	50	57.1	87.6	(65.0-115.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	28	16.0	175.3	(116.5-253.4)	Male	48	36.1	132.9	(98.0-176.2)
Female	17	20.4	83.5	(48.6-133.7)	<b><u>Ovary</u></b>				
<b><u>Colon / Rectum</u></b>					Female	41	41.8	98.1	(70.4-133.1)
Male	160	142.4	112.4	(95.6-131.2)	<b><u>Pancreas</u></b>				
Female	149	166.8	89.3	(75.6-104.9)	Male	30	30.7	97.6	(65.8-139.3)
<b><u>Esophagus</u></b>					Female	34	39.5	86.1	(59.6-120.3)
Male	28	25.8	108.4	(72.0-156.7)	<b><u>Prostate</u></b>				
Female	4	8.8	nc	(nc-nc)	Male	278	366.7	75.8	(67.2-85.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Stomach</u></b>				
Male	6	8.4	71.6	(26.2-156.0)	Male	34	23.8	142.6	(98.8-199.3)
Female	5	7.5	67.1	(21.6-156.5)	Female	36	18.7	192.8	(135.0-266.9)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	50	46.0	108.7	(80.7-143.3)	Male	5	13.9	35.8	(11.6-83.7)
Female	37	33.4	110.7	(77.9-152.6)	<b><u>Thyroid</u></b>				
<b><u>Larynx</u></b>					Male	8	14.8	54.0	(23.2-106.3)
Male	22	15.8	139.0	(87.1-210.5)	Female	38	49.6	76.5	(54.2-105.1)
Female	10	4.8	208.0	(99.6-382.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Leukemia</u></b>					Female	85	85.5	99.4	(79.4-122.9)
Male	31	33.8	91.8	(62.3-130.3)	<b><u>All Sites / Types</u></b>				
Female	37	31.3	118.2	(83.2-163.0)	Male	1342	1328.0	101.1	(95.7-106.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female	1327	1442.3	92.0	(87.1-97.1)
Male	34	22.3	152.7	(105.8-213.4)					
Female	11	9.6	114.5	(57.1-204.8)					
<b><u>Lung and Bronchus</u></b>									
Male	260	188.6	137.9	(121.6-155.7)					
Female	174	210.0	82.9	(71.0-96.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Falmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	62	57.2	108.4	(83.1-139.0)	Male	48	31.2	153.9	(113.5-204.0)
Female	17	20.5	82.9	(48.3-132.7)	Female	25	23.7	105.3	(68.1-155.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	8.6	104.8	(47.8-198.9)	Male	14	8.5	164.0	(89.6-275.1)
Female	10	7.4	135.2	(64.7-248.6)	Female	6	6.5	92.9	(33.9-202.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	41	27.2	150.8	(108.2-204.6)
Female	193	178.1	108.4	(93.6-124.8)	Female	25	25.3	98.8	(63.9-145.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	6.6	nc	(nc-nc)	Male	14	18.5	75.6	(41.3-126.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	84	76.7	109.5	(87.4-135.6)	Female	17	19.0	89.7	(52.2-143.6)
Female	52	73.4	70.8	(52.9-92.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	22	16.8	131.2	(82.2-198.7)
Male	12	13.9	86.1	(44.4-150.3)	Female	20	17.7	113.2	(69.1-174.8)
Female	4	4.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	229	202.1	113.3	(99.1-129.0)
Male	1	3.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	2.6	nc	(nc-nc)	Male	14	12.9	108.7	(59.4-182.4)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	7	8.0	87.4	(35.0-180.0)
Male	37	24.1	153.7	(108.2-211.9)	<b><u>Testis</u></b>				
Female	15	15.3	97.8	(54.7-161.4)	Male	9	4.4	202.7	(92.5-384.8)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	10	8.6	116.6	(55.8-214.5)	Male	5	6.7	74.8	(24.1-174.5)
Female	2	2.3	nc	(nc-nc)	Female	15	20.3	73.8	(41.3-121.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	26	16.9	153.6	(100.3-225.1)	Female	41	40.6	100.9	(72.4-137.0)
Female	19	13.2	144.1	(86.7-225.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	792	708.9	111.7	(104.1-119.8)
Male	3	11.7	nc	(nc-nc)	Female	650	649.4	100.1	(92.5-108.1)
Female	4	4.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	102	104.2	97.9	(79.8-118.8)					
Female	108	98.1	110.1	(90.3-132.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	42	40.2	104.4	(75.2-141.1)	Male	13	24.7	52.6	(28.0-90.0)
Female	18	16.5	109.2	(64.7-172.5)	Female	13	21.7	60.0	(31.9-102.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	7.7	nc	(nc-nc)	Male	4	6.2	nc	(nc-nc)
Female	4	7.0	nc	(nc-nc)	Female	5	5.2	96.0	(30.9-224.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	22	21.4	103.0	(64.5-156.0)
Female	129	148.1	87.1	(72.7-103.5)	Female	26	21.1	123.2	(80.4-180.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	6.4	94.0	(34.3-204.6)	Male	19	14.7	129.3	(77.8-202.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	46	55.8	82.4	(60.4-110.0)	Female	14	15.9	88.1	(48.1-147.8)
Female	51	60.8	83.9	(62.5-110.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	9	12.0	75.0	(34.2-142.3)
Male	10	10.2	98.0	(46.9-180.3)	Female	10	14.4	69.6	(33.3-128.0)
Female	4	3.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	129	145.4	88.7	(74.1-105.5)
Male	3	3.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	5	3.2	158.0	(50.9-368.6)	Male	7	9.3	75.6	(30.3-155.7)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	6.8	nc	(nc-nc)
Male	17	18.5	92.1	(53.6-147.5)	<b><u>Testis</u></b>				
Female	13	12.5	104.4	(55.5-178.5)	Male	9	6.2	144.4	(65.9-274.0)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	6	6.3	95.7	(34.9-208.2)	Male	1	6.3	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	12	20.3	59.2	(30.6-103.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	13.5	66.5	(30.3-126.2)	Female	31	32.5	95.3	(64.7-135.3)
Female	13	11.8	109.9	(58.5-188.0)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	453	526.4	86.1	(78.3-94.4)
Male	9	9.0	100.0	(45.6-189.9)	Female	469	542.3	86.5	(78.8-94.7)
Female	3	3.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	60	73.8	81.3	(62.1-104.7)					
Female	53	76.9	68.9	(51.6-90.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	5	2.6	192.0	(61.9-448.0)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	2	3.4	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.1	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.3	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	12	11.1	107.9	(55.7-188.5)
Male	0	0.2	nc	(nc-nc)	Female	12	8.9	135.4	(69.9-236.6)
Female	0	0.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	3	1.5	nc	(nc-nc)					
Female	3	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	16.4	103.7	(60.4-166.0)	Male	18	10.9	165.8	(98.2-262.1)
Female	5	6.1	82.3	(26.5-192.1)	Female	12	9.0	134.1	(69.2-234.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.4	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	6	9.2	65.3	(23.8-142.1)
Female	73	64.2	113.6	(89.1-142.9)	Female	8	8.0	99.4	(42.8-195.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.9	nc	(nc-nc)	Male	4	7.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	35	23.6	148.0	(103.1-205.9)	Female	10	6.6	152.1	(72.8-279.8)
Female	34	21.7	156.5	(108.3-218.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	5.1	nc	(nc-nc)
Male	4	4.5	nc	(nc-nc)	Female	6	5.2	115.8	(42.3-252.1)
Female	0	1.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	55	66.5	82.7	(62.3-107.7)
Male	1	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	5	3.8	132.1	(42.6-308.3)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	2.3	nc	(nc-nc)
Male	14	8.4	167.6	(91.5-281.1)	<b><u>Testis</u></b>				
Female	3	5.1	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	3	0.8	nc	(nc-nc)	Female	5	9.1	55.0	(17.7-128.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	5.6	107.2	(39.2-233.4)	Female	10	14.4	69.3	(33.2-127.4)
Female	9	4.3	207.7	(94.8-394.3)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	230	229.1	100.4	(87.8-114.3)
Male	4	4.1	nc	(nc-nc)	Female	248	217.6	114.0	(100.2-129.1)
Female	0	1.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	18	31.4	57.4	(34.0-90.7)					
Female	43	30.1	143.1	(103.5-192.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	47	67.5	69.6	(51.2-92.6)	Male	36	43.2	83.3	(58.3-115.3)
Female	19	26.1	72.9	(43.9-113.8)	Female	30	37.2	80.7	(54.5-115.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	13.2	83.6	(41.7-149.5)	Male	12	10.7	112.6	(58.1-196.6)
Female	9	11.4	79.0	(36.0-149.9)	Female	13	8.3	157.3	(83.7-269.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	43	36.8	117.0	(84.6-157.5)
Female	276	254.3	108.5	(96.1-122.1)	Female	29	34.1	85.1	(57.0-122.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	17	11.6	146.8	(85.5-235.1)	Male	21	26.2	80.1	(49.6-122.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	102	95.3	107.0	(87.3-129.9)	Female	21	26.7	78.7	(48.7-120.3)
Female	106	95.6	110.8	(90.7-134.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	15	17.7	84.9	(47.5-140.0)	Male	233	255.2	91.3	(79.9-103.8)
Female	8	5.1	158.2	(68.1-311.8)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	7	6.1	114.7	(46.0-236.4)	Male	8	11.1	72.0	(31.0-141.9)
Female	3	5.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	31	32.3	96.0	(65.2-136.2)	Female	58	56.3	102.9	(78.2-133.1)
Female	18	20.6	87.5	(51.9-138.4)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	11.0	81.8	(37.3-155.2)	Male	841	907.4	92.7	(86.5-99.2)
Female	5	3.0	164.5	(53.0-383.9)	Female	917	897.5	102.2	(95.7-109.0)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	24	22.7	105.9	(67.8-157.6)	<b><u>All Sites / Types</u></b>				
Female	23	18.7	123.0	(77.9-184.6)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	13	15.8	82.1	(43.7-140.4)	<b><u>All Sites / Types</u></b>				
Female	5	5.6	88.6	(28.5-206.7)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	113	125.1	90.3	(74.4-108.6)	<b><u>All Sites / Types</u></b>				
Female	116	123.8	93.7	(77.4-112.4)	<b><u>All Sites / Types</u></b>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	31	22.1	140.6	(95.5-199.6)	Male	16	16.0	99.8	(57.0-162.0)
Female	8	8.2	97.4	(41.9-191.9)	Female	13	14.1	92.1	(49.0-157.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	5.4	165.8	(75.6-314.7)	Male	8	3.7	218.5	(94.1-430.5)
Female	1	4.5	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	10	13.5	74.0	(35.4-136.0)
Female	93	94.9	98.0	(79.1-120.0)	Female	19	11.4	166.2	(100.0-259.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.9	nc	(nc-nc)	Male	6	10.0	60.0	(21.9-130.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	35	32.7	107.0	(74.5-148.9)	Female	16	9.6	166.9	(95.3-271.0)
Female	31	30.0	103.5	(70.3-146.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	7	6.9	101.3	(40.6-208.6)
Male	2	6.2	nc	(nc-nc)	Female	7	7.0	99.6	(39.9-205.3)
Female	2	1.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	131	88.3	148.3	(124.0-176.0)
Male	2	2.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	6	2.0	293.2	(107.1-638.3)	Male	2	5.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	3.2	nc	(nc-nc)
Male	12	12.0	100.2	(51.7-175.0)	<b><u>Testis</u></b>				
Female	1	7.2	nc	(nc-nc)	Male	6	4.8	125.8	(45.9-273.8)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	3.9	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	21	15.6	134.4	(83.2-205.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	7	8.4	83.4	(33.4-171.8)	Female	18	20.4	88.4	(52.4-139.7)
Female	9	6.7	134.9	(61.6-256.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	367	318.5	115.2	(103.7-127.6)
Male	3	5.9	nc	(nc-nc)	Female	319	315.3	101.2	(90.4-112.9)
Female	1	1.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	53	41.9	126.4	(94.6-165.3)					
Female	32	40.5	79.1	(54.1-111.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;